Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | IL2 | P60568 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | PYGL | P06737 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17240475 | 1.00 | AR (0.46) | ARALOX15ROCK2ALBIL2 | |
| SCHEMBL2137413 | 0.88 | AR (0.46) | ARALOX15ROCK2ALBIL2 | |
| SCHEMBL2137425 | 0.88 | AR (0.46) | ARALOX15ROCK2ALBIL2 | |
| SCHEMBL2137153 | 0.86 | AR (0.46) | ARALOX15ROCK2ALBIL2 | |
| SCHEMBL2137143 | 0.86 | AR (0.46) | ARALOX15ROCK2ALBIL2 | |
| SCHEMBL2944914 | 0.84 | CACNA1I (0.52) | ARALOX15ROCK2ALBIL2 | |
| SCHEMBL2944911 | 0.84 | CACNA1I (0.52) | ARALOX15ROCK2ALBIL2 | |
| SCHEMBL2133413 | 0.77 | CACNA1I (0.52) | ALBIL2FLT3PDE2APYGL | |
| SCHEMBL2133424 | 0.77 | CACNA1I (0.52) | ALBIL2FLT3PDE2APYGL | |
| SCHEMBL2136555 | 0.75 | CACNA1I (0.52) | ALOX15ROCK2FLT3PDE2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522140-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2016-12-20 | — | — | US | disclosed |
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC (JP) | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1H | AR 3195/4885ALOX15 4363/4885ROCK2 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.